There was an increase in the proportion of exclusive GLP-1 RA use from 88.2% in May to November 2022 to 96.1% from June 2025 to January 2026. HealthDay News — Adolescents and young adults are ...

PLEX100, an investigational prolonged-release local doxycycline product aimed at reducing surgical site infections in patients undergoing abdominal colorectal surgery.

Shionogi’s oral main protease inhibitor Xocova (ensitrelvir) is now available in the US to reduce the risk of symptomatic ...

Following an August 2025 CRL that raised no safety or manufacturing concerns, Saol provided additional survival analyses of existing clinical data to address FDA requirements without embarking on a ...

HealthDay News — Exposure to per- and polyfluoroalkyl substances (PFAS), or “forever chemicals,” during pregnancy and early life is associated with increased intestinal inflammation during childhood, ...

For patients with obstructive sleep apnea (OSA), hypoglossal nerve stimulation (HGNS) is associated with variable but potential long-term cardiovascular benefits, according to a study published online ...

HealthDay News — The 2026 American Heart Association/American College of Cardiology/multisociety guideline on the management of dyslipidemia has increased the US population recommended for primary ...

Freenome's newly approved blood test offers clinicians an alternative screening option for average-risk adults aged 45 and ...

HealthDay News — Emergency presentation (EP) for cancer diagnosis is common among older US adults and predicts persistently elevated mortality, according to a study published online July 14 in the ...

The votes are nonbinding, but they amount to a rebuke of the FDA’s own scientists who said the drugs have not been studied enough to know whether they are safe or effective.

Researchers found that the global morbidity gap increased from 8.8 to 10.7 years from 1990 to 2023, a 21.9% increase. HealthDay News — The global morbidity gap increased from 1990 to 2023, according ...

Supported by four phase 3 clinical trials, Simtriyo offers a novel triple-reuptake inhibition mechanism for managing core ADHD symptoms across pediatric and adult populations.